Citations

Showing 10 of 108083 citations.

Faculty Opinions recommendation of Crystalloid fluid therapy.
Kashani, Kianoush

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726589130.793538274 Get It

Faculty Opinions recommendation of Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure.
Kashani, Kianoush

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726074256.793538268 Get It

Faculty Opinions recommendation of Importance of abnormal chloride homeostasis in stable chronic heart failure.
Kashani, Kianoush

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726050900.793538269 Get It

Faculty Opinions recommendation of Association of hyperchloremia with hospital mortality in critically ill septic patients.
Kashani, Kianoush

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725624314.793538270 Get It

Faculty Opinions recommendation of Real-time urinary electrolyte monitoring after furosemide administration in surgical ICU patients with normal renal function.
Kashani, Kianoush

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.729509129.793538266 Get It

Phlpp inhibitors block pain and cartilage degradation associated with osteoarthritis
Hwang, Soyun M., Feigenson, Marina , Begun, Dana L., Shull, Lomeli C. , Culley, Kirsty L., Otero, Miguel , Ta, Lauren E., Bradley, Elizabeth W. , Shull, Lomeli Carpio, Bradley, Elizabeth W , Goldring, Mary B. , Kakar, Sanjeev , Westendorf, Jennifer J.

Mayo Clinic

Journal of Orthopaedic Research | October 25, 2017 | Volume: 36 | Issue: 5 | Pages: 1487-1497

10.1002/jor.23781 | PMID 29068480 Get It

ABSTRACTPhlpp protein phosphatases are abnormally abundant within human osteoarthritic articular chondrocytes and may contribute to the development of osteoarthritis. Mice lacking Phlpp1 were previously shown to be resistant to post‐traumatic osteoarthritis. Here a small molecule with therapeutic properties that inhibits Phlpp1 and Phlpp2 was tested for its ability to slow post‐traumatic OA in mice and to stimulate anabolic pathways in human articular cartilage from OA joints. PTOA was induced in male C57Bl/6 mice by surgically destabilizing the meniscus. Seven weeks after surgery, mice received a single intra‐articular injection of the Phlpp inhibitor NSC117079 or saline. Mechanical allodynia was measured with von Frey assays, mobility was tracked in an open field system, and cartilage damage was assessed histologically. A single intra‐articular injection of the Phlpp inhibitor NSC117079 attenuated mechanical allodynia and slowed articular cartilage degradation in joints with a destabilized meniscus. Animals treated with the Phlpp inhibitor 7 weeks after injury maintained normal activity levels, while those in the control group traveled shorter distances and were less active 3 months after the joint injury. NSC117079 also increased production of cartilage extracellular matrix components (glycosaminoglycans and aggrecan) in over 90% of human articular cartilage explants from OA patients and increased phosphorylation of Phlpp1 substrates (AKT2, ERK1/2, and PKC) in human articular chondrocytes. Our results indicate that Phlpp inhibitor NSC117079 is a novel osteoarthritis disease modifying drug candidate that may have palliative affects. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1487–1497, 2018.
Basal-Bolus Insulin Therapy in Postoperative Inpatients with Diabetes Mellitus: Directions for Future Quality-Improvement Initiatives
Apsey, Heidi A., Glasgow, Amy E. , Castro, Janna C. , Schlinkert, Richard T., Glasgow, Amy E. , Cook, Curtiss B. , Habermann, Elizabeth B. , Glasgow, Amy E

Mayo Clinic

Future Science OA | October 25, 2017 | Volume: 4 | Issue: 1 | Pages: No page available

10.4155/fsoa-2017-0099 | PMID 29255628 Get It

“Chondroblastoma‐like” epithelioid fibrous histiocytoma: A previously undescribed and potentially confusing variant
Martinez, Anthony P. , Zou, Youran , Billings, Steven D. , Folpe, Andrew L.

Mayo Clinic

Journal of Cutaneous Pathology | October 25, 2017 | Volume: 45 | Issue: 2 | Pages: 99-103

10.1111/cup.13068 | PMID 29068085 Get It

BackgroundEpithelioid benign fibrous histiocytoma has been considered a variant of fibrous histiocytoma, but is now considered a distinct entity, typically showing ALK expression. Most show typical morphological features, including an epidermal collarette and large, bland, epithelioid cells. We have recently encountered 2 examples showing an unusual pattern of pericellular calcification, a previously unreported finding.MethodsAvailable slides were reviewed and clinical follow‐up was obtained.ResultsThese lesions occurred on the chins of a 16‐year‐old and 19‐year‐old female and showed prominent pericellular calcification in addition to otherwise‐typical features of epithelioid fibrous histiocytoma. By immunohistochemistry, both lesions were intensely positive for ALK protein. Clinical follow‐up (available for 1 case) showed the patient to be disease‐free 5 months after excision.ConclusionsTo the best of our knowledge, epithelioid fibrous histiocytomas showing “chondroblastoma‐like” calcification have not been previously reported. The chief significance of this finding seems to be in its potential for confusion with other calcifying tumors of the skin and subcutis. Awareness that epithelioid fibrous histiocytomas may show this unusual morphological finding, careful morphological evaluation and ancillary immunohistochemical studies, including ALK protein, should allow for their confident diagnosis in essentially all instances.
Burden of hospitalization in clinically diagnosed peripheral artery disease: A community-based study
Arruda‐Olson, Adelaide M. , Pacha, Homam Moussa , Afzal, Naveed , Abram, S.E., Lewis, Bradley R., Isseh, Iyad , Haddad, Raad A., Bailey, Kent R. , Rooke, Thom W. , Moussa Pacha, Homam, Abram, Sara, Haddad, Raad, Scott, Christopher G. , Liu, Hongfang , Kullo, Iftikhar J.

Mayo Clinic

Vascular Medicine | October 25, 2017 | Volume: 23 | Issue: 1 | Pages: 23-31

10.1177/1358863x17736152 | PMID 29068255 Get It

The burden and predictors of hospitalization over time in community-based patients with peripheral artery disease (PAD) have not been established. This study evaluates the frequency, reasons and predictors of hospitalization over time in community-based patients with PAD. We assembled an inception cohort of 1798 PAD cases from Olmsted County, MN, USA (mean age 71.2 years, 44% female) from 1 January 1998 through 31 December 2011 who were followed until 2014. Two age- and sex-matched controls ( n = 3596) were identified for each case. ICD-9 codes were used to ascertain the primary reasons for hospitalization. Patients were censored at death or last follow-up. The most frequent reasons for hospitalization were non-cardiovascular: 68% of 8706 hospitalizations in cases and 78% of 8005 hospitalizations in controls. A total of 1533 (85%) cases and 2286 (64%) controls ( p < 0.001) were hospitalized at least once; 1262 (70%) cases and 1588 (44%) controls ( p < 0.001) ≥ two times. In adjusted models, age, prior hospitalization and comorbid conditions were independently associated with increased risk of recurrent hospitalizations in both groups. In cases, severe PAD (ankle–brachial index < 0.5) (HR: 1.25; 95% CI: 1.15, 1.36) and poorly compressible arteries (HR: 1.26; 95% CI: 1.16, 1.38) were each associated with increased risk for recurrent hospitalization. We demonstrate an increased rate of hospitalization in community-based patients with PAD and identify predictors of recurrent hospitalizations. These observations may inform strategies to reduce the burden of hospitalization of PAD patients.
Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
Lakshman, Arjun , Lacy, Martha Q. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Leung, Nelson , Kapoor, Prashant , Go, Ronald S. , Lin, Yi , Gonsalves, Wilson I. , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Hwa, Yi Lisa, Fonder, Amie L, Leung, Nelson , Go, Ronald S , Gonsalves, Wilson , Warsame, Rahma , Lakshman, Arjun , Russell, Stephen J , Dingli, David , Lin, Yi , Singh, Preet Paul , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | October 25, 2017 | Volume: 93 | Issue: 2 | Pages: 179-186

10.1002/ajh.24954 | PMID 29067723 Get It

AbstractExperience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE‐like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes of 141 patients with RRMM who received VPLRs at our center between 2006 and 2017 in an intent‐to‐treat analysis. Median age was 59.7 years and 66.7% of patients were male. A median of 2.2 years (range 0.02‐11.4) separated diagnosis of myeloma and inititation of VPLR. High‐risk cytogenetics were present in 52.4% patients. Patients received a median of 4 (range 1‐14) prior therapies, including stem cell transplant (SCT) in 66.7% patients. Ninety‐five (67.4%) patients received VDT PACE, 20 (14.2%) patients received VD PACE and 26 (18.4%) patients received other VPLRs. Patients received a median of 1 cycle (range 1‐9) of VPLR. We observed ≥ minimal response in 68.4%, ≥ partial response (PR) in 54.4% and ≥ very good PR in 10.3% patients. Median progression‐free survival was 3.1 months (95% CI, 1.9‐3.9) and median overall survival (OS) was 8.1 months (CI, 6.2‐9.9). One‐hundred and sixteen (82.3%) patients received some therapy after VPLR; 71 (61.2%) received systemic chemotherapy, while 45 (38.8%) underwent SCT. Median OS for those who received SCT after VPLR was 15.1 months (CI, 10.3‐20.8). Age ≥ 60 years (hazard ratio [HR] 2.3 [CI, 1.4‐3.7]; P = 0.0008) and R‐ISS III stage (HR‐ 2.4 [CI, 1.3‐4.0]; P = 0.003) predicted shorter OS in patients receiving VPLR. VPLRs are effective in heavily pre‐treated RRMM. In fit patients, SCT can be used to consolidate the response to VPLR.